Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 11 Multiple Myeloma 10 Fallopian Tube Neoplasms 7 Carcinoma, Ovarian Epithelial 6 Breast Neoplasms 6 Neoplasms, Plasma Cell 3 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 Lymphoma 2 Breast Neoplasms, Male 2 Waldenstrom Macroglobulinemia 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Patient Participation 1 Pancreatic Neoplasms 1 Ovarian Cancer Recurrent 1 Osteosarcoma 1 Neurofibrosarcoma 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Primary Effusion 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1

Interventions

pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Adenoviridae Infections × liposomal doxorubicin × Clear all

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡